Immunogenicity of a Meningococcal B Vaccine during a University Outbreak

被引:63
作者
Basta, Nicole E. [1 ,2 ,3 ,4 ]
Mahmoud, Adel A. F. [2 ]
Wolfson, Julian [1 ]
Ploss, Alexander [2 ]
Heller, Brigitte L. [2 ]
Hanna, Sarah [2 ]
Johnsen, Peter [2 ]
Izzo, Robin [2 ]
Grenfell, Bryan T. [2 ,3 ,4 ]
Findlow, Jamie [5 ]
Bai, Xilian [5 ]
Borrow, Ray [5 ]
机构
[1] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA
[2] Princeton Univ, Princeton, NJ 08544 USA
[3] Natl Inst Hlth Res, Bethesda, MD USA
[4] Natl Inst Policy Infect Dis Dynam, Bethesda, MD USA
[5] Manchester Royal Infirm, Vaccine Evaluat Unit, Publ Hlth England, Manchester, Lancs, England
基金
美国国家卫生研究院;
关键词
SERUM BACTERICIDAL ACTIVITY; SEROGROUP-B; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; STRAIN COVERAGE; INTERLABORATORY STANDARDIZATION; DISEASE RECOMMENDATIONS; OBSERVER-BLIND; 4CMENB; PREVENTION;
D O I
10.1056/NEJMoa1514866
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND In December 2013, a multicomponent meningococcal serogroup B (4CMenB) vaccine was used before licensure on the basis of special consideration by the Food and Drug Administration to respond to an outbreak of Neisseria meningitidis B at a U.S. university. Data suggested that vaccination would control the outbreak because isolates expressed antigens that were closely related to the vaccine antigens (factor H-binding protein [fHbp] and neisserial heparin-binding antigen). We quantified the immune responses induced by 4CMenB during the outbreak. METHODS We conducted a seroprevalence survey among students to assess vaccination status and collect serum specimens to quantify titers of serum bactericidal antibodies (SBA) with an assay that included human complement (hSBA). We compared the proportion of vaccinated and unvaccinated participants who were seropositive for the outbreak strain and for one closely related reference strain (44/76-SL, which included fHbp) and one mismatched reference strain (5/99, which included neisserial adhesin A), both of which were used in vaccine development. Seropositivity was defined as an hSBA titer of 4 or higher. RESULTS Among the 499 participants who received two doses of the 4CMenB vaccine 10 weeks apart, 66.1% (95% confidence interval [CI], 61.8 to 70.3) were seropositive for the outbreak strain, although the geometric mean titer was low at 7.6 (95% CI, 6.7 to 8.5). Among a random subgroup of 61 vaccinees who also received two doses but did not have a detectable protective response to the outbreak strain, 86.9% (95% CI, 75.8 to 94.2) were seropositive for the 44/76-SL strain, for which there was a geometric mean titer of 17.4 (95% CI, 13.0 to 23.2), whereas 100% of these vaccinees (95% CI, 94.1 to 100) were seropositive for the 5/99 strain and had a higher geometric mean titer (256.3; 95% CI, 187.3 to 350.7). The response to the outbreak strain was moderately correlated with the response to the 44/76-SL strain (Pearson's correlation, 0.64; P<0.001) but not with the response to the 5/99 strain (Pearson's correlation, -0.06; P = 0.43). CONCLUSIONS Eight weeks after the second dose of the 4CMenB vaccine was administered, there was no evidence of an hSBA response against the outbreak strain in 33.9% of vaccinees, although no cases of meningococcal disease caused by N. meningitidis B were reported among vaccinated students. (Funded by Princeton University and others.)
引用
收藏
页码:220 / 228
页数:9
相关论文
共 28 条
[1]   Meningococcal surrogates of protection - serum bactericidal antibody activity [J].
Borrow, R ;
Balmer, P ;
Miller, E .
VACCINE, 2005, 23 (17-18) :2222-2227
[2]   Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup B, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine [J].
Borrow, R ;
Aaberge, IS ;
Santos, GF ;
Eudey, TL ;
Oster, P ;
Glennie, A ;
Findlow, J ;
Hoiby, EA ;
Rosenqvist, E ;
Balmer, P ;
Martin, D .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2005, 12 (08) :970-976
[3]  
Borrow R, 2006, HDB MENINGOCOCCAL DI, P323
[4]  
Chang Qiuzhi, 2012, Clin Epidemiol, V4, P237, DOI 10.2147/CLEP.S28410
[5]   Capsule null locus meningococci: Typing of antigens used in an investigational multicomponent meningococcus serogroup B vaccine [J].
Claus, Heike ;
Jordens, Markus S. ;
Kriz, Pavla ;
Musilek, Martin ;
Jarva, Hanna ;
Pawlik, Marie-Christin ;
Meri, Seppo ;
Vogel, Ulrich .
VACCINE, 2012, 30 (02) :155-160
[6]  
Cohn AC, 2013, MMWR RECOMM REP, V62, P1
[7]   Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines [J].
Donnelly, John ;
Medini, Duccio ;
Boccadifuoco, Giuseppe ;
Biolchi, Alessia ;
Ward, Joel ;
Frasch, Carl ;
Moxon, E. Richard ;
Stella, Maria ;
Comanducci, Maurizio ;
Bambini, Stefania ;
Muzzi, Alessandro ;
Andrews, William ;
Chen, Jie ;
Santos, George ;
Santini, Laura ;
Boucher, Philip ;
Serruto, Davide ;
Pizza, Mariagrazia ;
Rappuoli, Rino ;
Giuliani, Marzia Monica .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (45) :19490-19495
[8]   Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study [J].
Elena Santolaya, Maria ;
O'Ryan, Miguel L. ;
Teresa Valenzuela, Maria ;
Prado, Valeria ;
Vergara, Rodrigo ;
Munoz, Alma ;
Toneatto, Daniela ;
Grana, Gabriela ;
Wang, Huajun ;
Clemens, Ralf ;
Dull, Peter M. .
LANCET, 2012, 379 (9816) :617-624
[9]   Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers [J].
Findlow, Jamie ;
Bai, Xilian ;
Findlow, Helen ;
Newton, Emma ;
Kaczmarski, Ed ;
Miller, Elizabeth ;
Borrow, Ray .
VACCINE, 2015, 33 (29) :3322-3330
[10]  
FINNE J, 1983, LANCET, V2, P355